A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

Sanofi-Aventis’s Novel Agent Emerges as an Effective Treatment for Prostate Cancer: Which Current Drugs Will Lose Market Share to Cabazitaxel?

Based on our Pharmacor advisory services entitled Prostate Cancer, Decision Resources is offering an exclusive analyst call entitled Sanofi-Aventis’s Novel Agent Emerges as an Effective Treatment for Prostate Cancer: Which Current Drugs Will Lose Market Share to Cabazitaxel? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

The recent news that Sanofi-Aventis’s cabazitaxel significantly improved overall survival in the second-line, metastatic prostate cancer setting compared with mitoxantrone (EMD Serono/Pfizer/Meda’s Novantrone/generics) will have a dramatic impact on the prostate cancer drug market. Following cabazitaxel’s launch, Sanofi-Aventis will dominate the cytotoxic chemotherapeutic space in metastatic prostate cancer as cabazitaxel will be used sequentially with Sanofi-Aventis’s currently-marketed first-line agent, Taxotere.

This 15-minute analyst call, presented by Analyst Andrew Merron, Ph.D., will answer the following questions:

How will the launch and uptake of cabazitaxel affect the sales of currently available prostate cancer therapies?
What is Decision Resources’ updated forecast for cabazitaxel and for the overall prostate cancer drug market?
What is the role of chemotherapy in prostate cancer and how does cabazitaxel’s novel mechanism of action make it one of the most promising agents in development?
What are the unmet needs that cabazitaxel will address and what factors will drive and/or constrain its uptake?

Dr. Merron will conduct a live Q & A session after the presentation.

Registration

Sanofi-Aventis’s Novel Agent Emerges as an Effective Treatment for Prostate Cancer: Which Current Drugs Will Lose Market Share to Cabazitaxel?

January 15, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Friday, January 15, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Andrew Merron, Ph.D., is a research analyst in the oncology department at Decision Resources. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath. His degree included a one-year work placement at the Institute of Neurology in London.

January 14, 2010
Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million?
Learn more

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.